The potential role of biomarkers in HIV preventive vaccine trials - Wikidata - awgldk - TriplyDB

The potential role of biomarkers in HIV preventive vaccine trials

The potential role of biomarkers in HIV preventive vaccine trials

http://www.wikidata.org/entity/Q34059957

about

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.Immunosignatures can predict vaccine efficacy.Biomarker validation of recent unprotected sexual intercourse in a prospective study of young women engaged in sex work in Phnom Penh, Cambodia.

P2860

Q33999615-E2B18421-4851-4016-A32B-AFE15AC47F19 Q34380788-1C27CB11-73E1-4C7D-8504-306EA354AFA6 Q37479132-89E051CB-5D1D-462C-8337-62F8D616C576

P2860

The potential role of biomarkers in HIV preventive vaccine trials

http://www.wikidata.org/entity/Q34059957

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

The potential role of biomarkers in HIV preventive vaccine trials

@ast

The potential role of biomarkers in HIV preventive vaccine trials

@en

The potential role of biomarkers in HIV preventive vaccine trials

@nl

type

label

The potential role of biomarkers in HIV preventive vaccine trials

@ast

The potential role of biomarkers in HIV preventive vaccine trials

@en

The potential role of biomarkers in HIV preventive vaccine trials

@nl

prefLabel

The potential role of biomarkers in HIV preventive vaccine trials

@ast

The potential role of biomarkers in HIV preventive vaccine trials

@en

The potential role of biomarkers in HIV preventive vaccine trials

@nl

P1433

Q34059957-8F2EE932-AB43-47C5-B4EE-E6A299B5AC81

P1476

Q34059957-22FEB6A7-3628-4927-B187-573A3FDAE074

P2093

Q34059957-1354D93A-18D4-4F8E-A61A-7735835898C2

Q34059957-1D255DC2-F164-4EB3-A5DA-7EFF2237B957

Q34059957-42DAE11F-5845-410B-8AF6-C9C5C479ADD1

Q34059957-697329B2-84E1-434F-8DE6-DD3C91AF1FF5

P2860

Q34059957-00DCAC0E-BB8D-455D-AAEC-597D80D1B455

Q34059957-03E768FD-BB49-4245-93DF-BBEE488EEBEC

Q34059957-04A579A2-0C20-4910-9EED-0507FD3E3D30

Q34059957-05E4A1D0-AF08-490C-8AC0-0054FC6F22F4

Q34059957-08427308-C416-4FD1-8198-A51D5D777FC2

Q34059957-0A072F63-2C82-46EE-ABFB-DE80218DFEB4

Q34059957-0C31E04D-A4FC-4E9D-8C29-3F57FA12286A

Q34059957-0F40D292-74DE-4F8D-98F6-DD82869B45EF

Q34059957-0F713C08-57C6-45D5-905F-94222C1689AD

Q34059957-111BF883-C379-4E11-B31C-AB4366947296

P304

Q34059957-ABBDD982-0741-4EE6-95DD-E878F5866C3D

P31

Q34059957-19D0980A-F838-4AB2-85C5-179C06141690

P356

Q34059957-18061D3B-8436-42AC-9CDD-6B8A083B0EE9

P407

Q34059957-07769846-7DAA-4BBD-A8D7-DE5B0C083126

P433

Q34059957-5774F738-86E1-4DE8-AF71-0931507AE0BD

P478

Q34059957-A34F2A11-38A5-43F7-9153-57A6FB0640AA

P50

Q34059957-2B01AB98-B6F7-41AF-B2B1-C10EB9870120

Q34059957-ABA2F877-4CB1-4AD2-968E-5605F9A490A3

P577

Q34059957-0AD99800-AC34-43CA-993C-BC6B1C66F4E1

P698

Q34059957-E45375B3-FE0D-4B97-AF31-8936F74352AF

P921

Q34059957-D245E6DA-1048-42D2-B807-C7296E07965C

P932

Q34059957-5A6923FC-047D-4801-A5EA-638811F69255

P356

QAI.0B013E3181ADCBBE

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

The potential role of biomarkers in HIV preventive vaccine trials

@en

P2093

Ann Duerr

http://www.w3.org/2001/XMLSchema#string

Ellen Maclachlan

http://www.w3.org/2001/XMLSchema#string

Jorge Sanchez

http://www.w3.org/2001/XMLSchema#string

Ruanne Barnabas

http://www.w3.org/2001/XMLSchema#string

P2860

Are trends in HIV, gonorrhoea, and syphilis worsening in western Europe?

Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study.

Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials.

Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team.

Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City.

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases.

P304

536-545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3181ADCBBE

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19512938

http://www.w3.org/2001/XMLSchema#string

P921

P932

2920071

http://www.w3.org/2001/XMLSchema#string